Dianthus Therapeutics (NASDAQ:DNTH) CAO Edward Carr Sells 20,000 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer owned 20,000 shares in the company, valued at approximately $2,027,600. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Dianthus Therapeutics Stock Performance

DNTH opened at $96.81 on Friday. The stock has a market capitalization of $5.29 billion, a PE ratio of -23.33 and a beta of 1.24. The stock’s 50 day moving average price is $107.03 and its 200-day moving average price is $92.84. Dianthus Therapeutics, Inc. has a 52-week low of $32.22 and a 52-week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth about $401,990,000. Wellington Management Group LLP increased its stake in shares of Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after acquiring an additional 634,099 shares in the last quarter. Polar Capital Holdings Plc lifted its position in Dianthus Therapeutics by 34.3% during the 4th quarter. Polar Capital Holdings Plc now owns 1,004,728 shares of the company’s stock valued at $41,405,000 after acquiring an additional 256,725 shares during the period. Jennison Associates LLC purchased a new position in Dianthus Therapeutics during the 1st quarter valued at about $40,713,000. Finally, BNP Paribas Financial Markets boosted its stake in Dianthus Therapeutics by 1,275.3% during the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after acquiring an additional 441,156 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of research reports. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $129.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.